Actuate Therapeutics (NASDAQ:ACTU) Shares Down 3.6% – Time to Sell?

Actuate Therapeutics, Inc. (NASDAQ:ACTU)’s share price fell 3.6% during trading on Monday . The stock traded as low as $4.17 and last traded at $4.25. 18,594 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 67,262 shares. The stock had previously closed at $4.41.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ACTU shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Actuate Therapeutics in a research report on Wednesday, November 19th. Finally, Wall Street Zen cut Actuate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.33.

Actuate Therapeutics Trading Down 3.6%

The firm has a market cap of $98.77 million, a PE ratio of -4.89 and a beta of -0.15. The company’s 50-day moving average is $6.10 and its 200 day moving average is $6.84.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02.

Insiders Place Their Bets

In related news, Director Todd S. Thomson sold 280,000 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $5.80, for a total transaction of $1,624,000.00. Following the transaction, the director directly owned 904,795 shares of the company’s stock, valued at approximately $5,247,811. The trade was a 23.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 69.34% of the company’s stock.

Hedge Funds Weigh In On Actuate Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. BIOS Capital Management LP increased its holdings in shares of Actuate Therapeutics by 0.9% in the 3rd quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock valued at $67,234,000 after purchasing an additional 84,917 shares during the period. Voss Capital LP boosted its stake in shares of Actuate Therapeutics by 213.2% during the 3rd quarter. Voss Capital LP now owns 896,278 shares of the company’s stock valued at $5,996,000 after buying an additional 610,138 shares during the period. Vanguard Group Inc. boosted its position in Actuate Therapeutics by 19.5% during the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock valued at $2,114,000 after purchasing an additional 51,546 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Actuate Therapeutics by 42.9% during the 4th quarter. Geode Capital Management LLC now owns 207,744 shares of the company’s stock valued at $1,271,000 after buying an additional 62,332 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in Actuate Therapeutics in the fourth quarter valued at approximately $579,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.